) is one step closer to getting its new Alzheimer's treatment approved by the Food and Drug Administration after a panel voted to recommend its use. BMO Capital Markets Managing Director Evan Seigerman joins Market Domination to discuss how the drug will fit into the drug market.
They slow the cognition and function declines that we see when it comes to Alzheimer's disease, you get about six months of kind of a benefit which frankly, if your parent had it, that would be a really good thing.It's infusions that are, you know, twice a month.So it is, there's a lot of infrastructure.
So it's a lot of infrastructure um to get these patients the drug when you, and when you try to look at this, the mark of these treatments for Alzheimer's and you try to model it, like, how big is it now?I think over time between these two products, it could be 1015 $20 billion.
So there is opportunity elsewhere outside of metabolic disease and, and finally, one, you, you just look at the stock and it's just a monster.So, so what are the next catalysts?Why do we Yeah, why do we keep liking the stock?
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: YahooFinanceCA - 🏆 47. / 63 Read more »